BR112018015164A2 - oligonucleotídeo de fita simples - Google Patents
oligonucleotídeo de fita simplesInfo
- Publication number
- BR112018015164A2 BR112018015164A2 BR112018015164A BR112018015164A BR112018015164A2 BR 112018015164 A2 BR112018015164 A2 BR 112018015164A2 BR 112018015164 A BR112018015164 A BR 112018015164A BR 112018015164 A BR112018015164 A BR 112018015164A BR 112018015164 A2 BR112018015164 A2 BR 112018015164A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleotide sequence
- oligonucleotide
- single stranded
- hybridization
- stranded oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 125000003729 nucleotide group Chemical group 0.000 abstract 10
- 239000002773 nucleotide Substances 0.000 abstract 9
- 238000009396 hybridization Methods 0.000 abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
a presente invenção refere-se a um oligonucleotídeo de fita simples que é capaz de controlar um gene alvo com alta eficiência e pode ser facilmente produzido. o oligonucleotídeo de fita simples é representado pela fórmula x-l-y onde x e y hibridizam através de uma primeira porção de sequência de nucleotídeos e uma segunda porção de sequência de nucleotídeos. x é composto por 7 a 100 nucleotídeos, contém pelo menos um nucleotídeo modificado, e tem uma primeira sequência de nucleotídeos que é capaz de hibridização com um segundo oligonucleotídeo e contém pelo menos quatro nucleotídeos contíguos reconhecidos por rnase h. y é composto por 4 a 100 nucleotídeos, e tem uma segunda sequência de nucleotídeos que é capaz de hibridização com um segundo oligonucleotídeo e contém pelo menos um ribonucleotídeo. pelo menos uma de sequência de nucleotídeos x e sequência de nucleotídeos y tem uma sequência antissentido capaz de hibridização com um rna alvo. l é um grupo derivado de um terceiro oligonucleotídeo que é degradado sob condições fisiológicas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016012804 | 2016-01-26 | ||
JP2016158833 | 2016-08-12 | ||
PCT/JP2017/002831 WO2017131124A1 (ja) | 2016-01-26 | 2017-01-26 | 一本鎖オリゴヌクレオチド |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018015164A2 true BR112018015164A2 (pt) | 2018-12-26 |
Family
ID=59398721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018015164A BR112018015164A2 (pt) | 2016-01-26 | 2017-01-26 | oligonucleotídeo de fita simples |
Country Status (10)
Country | Link |
---|---|
US (2) | US11530409B2 (pt) |
EP (1) | EP3409779A4 (pt) |
JP (3) | JP6988481B2 (pt) |
CN (2) | CN116064544A (pt) |
AU (1) | AU2017211461B2 (pt) |
BR (1) | BR112018015164A2 (pt) |
CA (1) | CA3023222A1 (pt) |
MX (2) | MX2018009090A (pt) |
TW (2) | TWI803455B (pt) |
WO (1) | WO2017131124A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116064544A (zh) | 2016-01-26 | 2023-05-05 | 日产化学株式会社 | 单链寡核苷酸 |
CA3052801A1 (en) * | 2017-02-06 | 2018-08-09 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
US11555188B2 (en) | 2017-07-26 | 2023-01-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
AU2019237599A1 (en) | 2018-03-20 | 2020-11-12 | Nissan Chemical Corporation | Antisense oligonucleotide having reduced toxicity |
US20220162607A1 (en) | 2019-03-14 | 2022-05-26 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
EP4098747A1 (en) | 2020-01-31 | 2022-12-07 | Sanwa Kagaku Kenkyusho Co., Ltd. | Antisense oligonucleotide of atn1 |
EP4116419A1 (en) | 2020-03-04 | 2023-01-11 | Nissan Chemical Corporation | Antisense oligonucleotide of calm2 |
JPWO2022211129A1 (pt) * | 2021-04-01 | 2022-10-06 | ||
EP4353266A1 (en) | 2021-05-31 | 2024-04-17 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08154687A (ja) | 1994-12-12 | 1996-06-18 | Yamanouchi Pharmaceut Co Ltd | アンチセンスオリゴヌクレオチド及び抗ウイルス剤 |
JPH09110894A (ja) | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | ハイブリッドdna/rnaオリゴヌクレオチド及び抗ウイルス剤 |
US20040171028A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
JPH11137260A (ja) | 1997-11-06 | 1999-05-25 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス環状ダンベル型rna−dnaキメラ化合物及び抗インフルエンザウイルス剤 |
AU6055299A (en) | 1998-09-21 | 2000-04-10 | Ribozyme Pharmaceuticals, Inc. | Hairpin hybridizer molecules for modulation of gene expression |
AU2395900A (en) * | 1998-12-31 | 2000-07-31 | Gene Logic, Inc. | Assay device comprising mixed probes |
MXPA01011708A (es) * | 1999-06-25 | 2003-09-10 | Insight Strategy & Marketing | Polinucleotidos que codifican polipeptidos distantemente homologos a heparanasa. |
EP1627061B1 (en) * | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
US20070032441A1 (en) * | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
EP2221377B2 (en) * | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
WO2003068795A1 (fr) | 2002-02-13 | 2003-08-21 | Takeshi Imanishi | Analogues de nucleoside et derive d'oligonucleotide comprenant un analogue nucleotidique de ces composes |
AU2003213203A1 (en) | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incorporated | Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways |
GB0205455D0 (en) * | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
EP2258847B2 (en) | 2002-08-05 | 2020-07-01 | Silence Therapeutics GmbH | Futher novel forms of interfering RNA molecules |
US20040058886A1 (en) | 2002-08-08 | 2004-03-25 | Dharmacon, Inc. | Short interfering RNAs having a hairpin structure containing a non-nucleotide loop |
AU2003291721A1 (en) * | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
AU2003299864A1 (en) | 2002-12-27 | 2004-07-29 | P. Radhakrishnan | Sirna compounds and methods for the downregulation of gene expression |
JP4948163B2 (ja) * | 2003-05-23 | 2012-06-06 | サーナ・セラピューティクス・インコーポレイテッド | 化学修飾した低分子干渉核酸(siNA)を使用する遺伝子発現のRNA干渉仲介抑制 |
CA2528597C (en) | 2003-06-11 | 2014-08-05 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
CN101155918A (zh) * | 2005-02-01 | 2008-04-02 | 爱尔康公司 | RNAi介导的高眼压靶标的抑制 |
EP2052079A2 (en) * | 2006-07-17 | 2009-04-29 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
CN101301478A (zh) * | 2007-05-10 | 2008-11-12 | 贝勒医学院 | 以低氧诱导因子1-α(HIF1α)作为靶标的G-四合体寡核苷酸 |
EP2321414B1 (en) * | 2008-07-25 | 2018-01-10 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
EP2454371B1 (en) | 2009-07-13 | 2021-01-20 | Somagenics, Inc. | Chemical modification of small hairpin rnas for inhibition of gene expression |
WO2011052436A1 (ja) | 2009-10-29 | 2011-05-05 | 国立大学法人大阪大学 | 架橋型人工ヌクレオシドおよびヌクレオチド |
MX2012010479A (es) * | 2010-03-08 | 2012-10-09 | Monsanto Technology Llc | Moleculas polinucleotidicas para regulacion genetica en plantas. |
DK2558578T3 (en) | 2010-04-13 | 2016-01-25 | Life Technologies Corp | CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
KR101894701B1 (ko) | 2010-08-03 | 2018-09-04 | 가부시키가이샤 보낙 | 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 |
WO2013040429A1 (en) * | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
CA3106312A1 (en) | 2011-12-16 | 2013-06-20 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
US9528111B2 (en) | 2012-01-07 | 2016-12-27 | Bonac Corporation | Single-stranded nucleic acid molecule having amino acid backbone |
US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
CN103114131B (zh) * | 2012-11-30 | 2018-10-02 | 珠海市坤元农业科技有限公司 | 一种引物中部序列干扰pcr技术 |
CN103333890B (zh) * | 2012-12-21 | 2015-04-15 | 厦门成坤生物技术有限公司 | 治疗乙型病毒性肝炎的rna干扰制剂 |
IL284593B2 (en) | 2013-05-01 | 2023-02-01 | Ionis Pharmaceuticals Inc | Compositions and methods for modulation of hbv and ttr expression |
US11028387B2 (en) | 2013-05-30 | 2021-06-08 | National University Corporation Tokyo Medical And Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
CN104419702A (zh) * | 2013-09-04 | 2015-03-18 | 北京中康万达医药科技有限公司 | 一种基于生物信息学筛选siRNA的方法 |
CN106068324B (zh) | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
WO2015105083A1 (ja) | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
WO2015113922A1 (en) * | 2014-01-30 | 2015-08-06 | Roche Innovation Center Copenhagen A/S | Poly oligomer compound with biocleavable conjugates |
JPWO2016152352A1 (ja) * | 2015-03-20 | 2018-01-11 | 国立大学法人名古屋大学 | メラノーマ特異的バイオマーカー及びその利用 |
CN116064544A (zh) * | 2016-01-26 | 2023-05-05 | 日产化学株式会社 | 单链寡核苷酸 |
US11878060B2 (en) * | 2016-08-07 | 2024-01-23 | Novartis Ag | mRNA-mediated immunization methods |
CA3052801A1 (en) * | 2017-02-06 | 2018-08-09 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
US11555188B2 (en) * | 2017-07-26 | 2023-01-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
AU2019237599A1 (en) * | 2018-03-20 | 2020-11-12 | Nissan Chemical Corporation | Antisense oligonucleotide having reduced toxicity |
EP3650559B1 (en) * | 2018-11-08 | 2022-06-29 | Siemens Healthcare GmbH | Direct rna nanopore sequencing with help of a stem-loop polynucleotide |
WO2020154344A1 (en) * | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
EP4116419A1 (en) * | 2020-03-04 | 2023-01-11 | Nissan Chemical Corporation | Antisense oligonucleotide of calm2 |
-
2017
- 2017-01-26 CN CN202211379310.XA patent/CN116064544A/zh active Pending
- 2017-01-26 CN CN201780008239.5A patent/CN108884462B/zh active Active
- 2017-01-26 TW TW106103330A patent/TWI803455B/zh active
- 2017-01-26 JP JP2017563832A patent/JP6988481B2/ja active Active
- 2017-01-26 EP EP17744354.6A patent/EP3409779A4/en active Pending
- 2017-01-26 BR BR112018015164A patent/BR112018015164A2/pt unknown
- 2017-01-26 WO PCT/JP2017/002831 patent/WO2017131124A1/ja active Application Filing
- 2017-01-26 CA CA3023222A patent/CA3023222A1/en active Pending
- 2017-01-26 TW TW112115168A patent/TW202334427A/zh unknown
- 2017-01-26 AU AU2017211461A patent/AU2017211461B2/en active Active
- 2017-01-26 US US16/073,114 patent/US11530409B2/en active Active
- 2017-01-26 MX MX2018009090A patent/MX2018009090A/es unknown
-
2018
- 2018-07-25 MX MX2023002818A patent/MX2023002818A/es unknown
-
2021
- 2021-12-01 JP JP2021195231A patent/JP7435583B2/ja active Active
-
2022
- 2022-11-11 US US18/054,660 patent/US20230203498A1/en active Pending
-
2024
- 2024-02-08 JP JP2024017718A patent/JP2024056807A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022050389A (ja) | 2022-03-30 |
US11530409B2 (en) | 2022-12-20 |
CN116064544A (zh) | 2023-05-05 |
TW202334427A (zh) | 2023-09-01 |
WO2017131124A1 (ja) | 2017-08-03 |
TWI803455B (zh) | 2023-06-01 |
JP2024056807A (ja) | 2024-04-23 |
US20190119683A1 (en) | 2019-04-25 |
MX2023002818A (es) | 2023-03-17 |
JPWO2017131124A1 (ja) | 2018-11-15 |
MX2018009090A (es) | 2019-03-28 |
CN108884462B (zh) | 2022-11-25 |
TW201738376A (zh) | 2017-11-01 |
CA3023222A1 (en) | 2017-08-03 |
CN108884462A (zh) | 2018-11-23 |
AU2017211461A1 (en) | 2018-09-13 |
EP3409779A4 (en) | 2019-07-03 |
JP6988481B2 (ja) | 2022-01-05 |
AU2017211461B2 (en) | 2023-01-12 |
EP3409779A1 (en) | 2018-12-05 |
US20230203498A1 (en) | 2023-06-29 |
JP7435583B2 (ja) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018015164A2 (pt) | oligonucleotídeo de fita simples | |
Borah | Primer designing for PCR | |
MX2021014769A (es) | Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos. | |
BR112016019267A2 (pt) | métodos e composições para perfil de dna | |
Mei et al. | A facile and specific assay for quantifying microRNA by an optimized RT-qPCR approach | |
JP2017002079A5 (pt) | ||
WO2017037304A3 (en) | An assembly system for a eukaryotic cell | |
BR112016029548A2 (pt) | método de sequenciamento de um ácido nucleico e sistema de sonda biológico multicomponente | |
BR112014018940A8 (pt) | Método e kit para detecção de uma sequência de ácido nucleico alvo | |
JP2016537990A5 (pt) | ||
CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
JP2017515484A5 (pt) | ||
MY157531A (en) | Td probe and its uses | |
PE20190843A1 (es) | Arn de direccion a adn generico | |
WO2018031818A3 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
AR100946A1 (es) | Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn | |
JP2012223202A5 (pt) | ||
MX361191B (es) | Detección de secuencia de ácidos nucleicos objetivo por ensayo de escisión de pto y no hibridación dependiente de la extensión. | |
MX2019009305A (es) | Oligonucleotido de cadena simple. | |
JP2014030431A5 (pt) | ||
MX2020010802A (es) | Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm. | |
DE60332775D1 (de) | Dopplezweck -Primer und -Proben für verbesserte Hybridisierungsassays durch Zerstörung von Sekundärstrukturen | |
Xu et al. | Real-time quantitative nicking endonuclease-mediated isothermal amplification with small molecular beacons | |
JP2018068317A5 (pt) | ||
Sakhabutdinova et al. | Inhibition of nonspecific polymerase activity using poly (aspartic) acid as a model anionic polyelectrolyte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023003774-0 PROTOCOLO 870230017145 EM 28/02/2023 16:34. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |